Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun
April 16 2020 - 8:00AM
InvestorsHub NewsWire
Cannabis? CBD? That’s Old News, A
New Sector Bull Run Has Begun
New York, NY -- April 16, 2020 --
InvestorsHub NewsWire -- via Traders
News Source -- Traders
News Source, a leading independent equity research and corporate
access firm focused on small cap growth companies’ issues their
latest research “The Next Hot Sector”
Northwest Biotherapeutics,
Inc. (OTCQB:
NWBO) is a biotechnology company developing DCVax®
personalized immune therapies for solid tumor cancers. The
Company's lead program is a 331-patient Phase III trial in newly
diagnosed Glioblastoma multiforme (GBM). The Company is also
pursuing development of DCVax®-Direct for inoperable solid tumor
cancers. It has completed a 40-patient Phase I trial and is
preparing for Phase II trials. The Company previously
conducted a Phase I/II trial with DCVax-L for advanced ovarian
cancer together with the University of
Pennsylvania.
Amarin Corporation plc
(NASDAQ:
AMRN) is focused on its lead product, VASCEPA®
(icosapent ethyl) capsules, is available by prescription in the
United States and an increasing number of other countries. VASCEPA®
(icosapent ethyl), capsules, was originally approved in 2012 to
reduce severely elevated levels of triglycerides. The drug’s
approval was expanded in 2019 as an adjunct to maximally tolerated
statin therapy to reduce the risk of cardiovascular events in
certain adults with elevated triglyceride levels of 150 milligrams
per deciliter or higher and other cardiovascular risk factors. On
March 6th, the company reaffirmed its outlook for 2020
with revenues expected to range from $650 million to $700
million.
Ever wish you were aware of a hot
new sector before it experiences explosive growth? Hot new sector
in its infancy gaining traction now READ
MORE
Copy and paste to browser may be
required https://www.industrynews.tips/
Anavex Life Sciences Corp.
(NASDAQ:
AVXL) is a clinical-stage biopharmaceutical company
developing therapeutics for the treatment of Alzheimer’s disease,
Parkinson’s disease and Rett syndrome and other central nervous
system (CNS) diseases. recently, the company announced the
publication of foundational data for ANAVEX®2-73 (blarcamesine) in
Multiple Sclerosis (MS). The data showed that
ANAVEX®2-73, in an invitro study, impacts the central nervous
system in a unique way. There are effective disease-modifying
therapies (DMTs) approved for treatment of patients with relapsing
remitting MS, however, none of these DMTs are cures and many have
significant side effects.
Kiwa Bio-Tech Products
Group Corporation (OTCQB:
KWBT) is an agricultural company that develops,
manufactures and markets bio-fertilizers for use in the
multi-billion China agriculture and aquaculture markets and the
developer of smart soil remediation technology for use in
agriculture markets. Wade Li has recently been installed as the new
CEO. Focusing on China’s nearly 35 billion USD new fertilizer
market, as well as nearly trillion USD soil remediation market,
Kiwa will rely on its existing business to expand fertilizer market
share, to obtain soil remediation market share.
Ever wish you were aware of a hot
new sector before it experiences explosive growth? Hot new sector
in its infancy gaining traction now READ
MORE
Copy and paste to browser may be
required – https://www.industrynews.tips/
Disclosure
Traders News Source LLC (TNS)
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
small and micro-cap equity markets. TNS has two distinct and
independent departments. One department produces non-sponsored
analyst certified content generally in the form of press releases,
articles and reports covering equities listed on NYSE, NASDAQ and
OTC exchanges. The other produces sponsored content (in most cases
not reviewed by a registered analyst), which typically consists of
compensated investment newsletters, articles and reports covering
listed stocks and micro-caps. Such sponsored content is outside the
scope of procedures detailed below.
PRESS RELEASE
PROCEDURES
The sponsored and non-sponsored
content contained herein has been prepared by a writer (the
"Author") and is fact checked and reviewed by a third-party
research service company (the "Reviewer") represented by a
chartered financial analyst, for further information on analyst
credentials, please email editor@tradersnewssource.com.
TNS LLC provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written, and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author per
the procedures outlined by TNS. TNS is not entitled to veto or
interfere in the application of such procedures by the third-party
research service company to the articles, documents, or reports.
Unless otherwise noted, any content outside of this document has no
association with the Author or the Reviewer in any
way.
NO WARRANTY
TNS, the Author, and the Reviewer
are not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake, or
shortcoming. No liability is accepted whatsoever for any direct,
indirect, or consequential loss arising from the use of this
document. TNS, the Author, and the Reviewer expressly disclaim any
fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Additionally, TNS, the Author, and
the Reviewer do not (1) guarantee the accuracy, timeliness,
completeness, or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as
an offering, recommendation, or a solicitation of an offer to buy
or sell the securities mentioned or discussed and is to be used for
informational purposes only. Please read all associated disclosures
and disclaimers in full before investing. Neither TNS nor any party
affiliated with us is a registered investment adviser or
broker-dealer with any agency or in any jurisdiction whatsoever. To
read our report(s), disclosures, or for more information, visit
http://www.tradersnewssource.com.
For any questions, inquiries, or
comments reach out to us directly. If you're a company we are
covering and wish to no longer be featured on our coverage list,
contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial
Analyst® are registered trademarks owned by CFA
Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News
Source
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024